121 related articles for article (PubMed ID: 25692755)
1. [The possibility of the serum concentration of osteocalcin determination in lung cancer patients with suspected bone metastases].
Weissensteiner J; Babušíková E
Klin Onkol; 2015; 28(1):51-6. PubMed ID: 25692755
[TBL] [Abstract][Full Text] [Related]
2. Is there any correlation between levels of serum ostepontin, CEA, and FDG uptake in lung cancer patients with bone metastasis?
Ayan AK; Erdemci B; Orsal E; Bayraktutan Z; Akpinar E; Topcu A; Turkeli M; Seven B
Rev Esp Med Nucl Imagen Mol; 2016; 35(2):102-6. PubMed ID: 26521996
[TBL] [Abstract][Full Text] [Related]
3. The value of human epididymis protein 4 (HE4) as a serum tumor marker for accurate bone metastases finding by whole-body bone scintigraphy in lung cancer patients.
Weissensteiner J; Babusikova E
Neoplasma; 2019 Nov; 66(6):1024-1030. PubMed ID: 31307200
[TBL] [Abstract][Full Text] [Related]
4. Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients.
Karapanagiotou EM; Terpos E; Dilana KD; Alamara C; Gkiozos I; Polyzos A; Syrigos KN
Med Oncol; 2010 Jun; 27(2):332-8. PubMed ID: 19373566
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of bone markers for detection of bone metastases in lung cancer patients.
Alataş F; Alataş O; Metintaş M; Colak O; Erginel S; Harmanci E
Clin Biochem; 2002 Jun; 35(4):293-6. PubMed ID: 12135691
[TBL] [Abstract][Full Text] [Related]
6. Bone Metabolism of the Patient with a Malignant Melanoma during the Entry Examination and the Check-up of Whole-body Bone Scintigraphy.
Weissensteiner J; Babušíková E
Prague Med Rep; 2016; 117(2-3):129-134. PubMed ID: 27668530
[TBL] [Abstract][Full Text] [Related]
7. Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer.
Kong QQ; Sun TW; Dou QY; Li F; Tang Q; Pei FX; Tu CQ; Chen ZQ
Int J Biol Markers; 2007; 22(3):214-20. PubMed ID: 17922466
[TBL] [Abstract][Full Text] [Related]
8. The role of whole-body bone scanning and clinical factors in detecting bone metastases in patients with non-small cell lung cancer.
Erturan S; Yaman M; Aydin G; Uzel I; Müsellim B; Kaynak K
Chest; 2005 Feb; 127(2):449-54. PubMed ID: 15705981
[TBL] [Abstract][Full Text] [Related]
9. Markers of bone metastases in breast and lung cancers.
Bilgin E; Yasasever V; Soydinc HO; Yasasever CT; Ozturk N; Duranyildiz D
Asian Pac J Cancer Prev; 2012; 13(9):4331-4. PubMed ID: 23167338
[TBL] [Abstract][Full Text] [Related]
10. Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma.
Begić A; Kucukalić-Selimović E; Obralić N; Durić O; Lacević N; Skopljak A
Bosn J Basic Med Sci; 2006 Feb; 6(1):75-7. PubMed ID: 16533185
[TBL] [Abstract][Full Text] [Related]
11. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K
J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of pentavalent Tc-99m DMSA scintigraphy in small cell and nonsmall cell lung cancers.
Atasever T; Gündoğdu C; Vural G; Kapucu LO; Karalezli A; Unlü M
Nuklearmedizin; 1997 Oct; 36(7):223-7. PubMed ID: 9394361
[TBL] [Abstract][Full Text] [Related]
13. Serum osteocalcin in monitoring bone metastases in advanced prostatic cancer.
Marcellini M; De Carli P; Abbolito MR; Mainiero G; Cantiani R
Eur Urol; 1992; 21 Suppl 1():102-4. PubMed ID: 1385126
[TBL] [Abstract][Full Text] [Related]
14. Differentiation of brain metastases from small and non-small lung cancers using apparent diffusion coefficient (ADC) maps.
Müller SJ; Khadhraoui E; Neef NE; Riedel CH; Ernst M
BMC Med Imaging; 2021 Apr; 21(1):70. PubMed ID: 33858368
[TBL] [Abstract][Full Text] [Related]
15. The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer.
Bayrak SB; Ceylan E; Serter M; Karadağ F; Demir E; Çildağ O
Int J Clin Oncol; 2012 Apr; 17(2):112-8. PubMed ID: 21691728
[TBL] [Abstract][Full Text] [Related]
16. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.
Lumachi F; Marino F; Fanti G; Chiara GB; Basso SM
Anticancer Res; 2011 Nov; 31(11):3879-81. PubMed ID: 22110213
[TBL] [Abstract][Full Text] [Related]
17. Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer?
Arai Y; Takeuchi H; Oishi K; Yoshida O
Prostate; 1992; 20(3):169-77. PubMed ID: 1374180
[TBL] [Abstract][Full Text] [Related]
18. Is there a role of whole body bone scan in early stages of non small cell lung cancer patients.
Iordanidou L; Trivizaki E; Saranti S; Georgakopoulos A; Bolanos N; Baltagiannis N; Koutsiouba P
J BUON; 2006; 11(4):491-7. PubMed ID: 17309183
[TBL] [Abstract][Full Text] [Related]
19. Markers of bone turnover in patients with lung cancer.
Dane F; Turk HM; Sevinc A; Buyukberber S; Camci C; Tarakcioglu M
J Natl Med Assoc; 2008 Apr; 100(4):425-8. PubMed ID: 18481482
[TBL] [Abstract][Full Text] [Related]
20. Correlation of decreased survival and IL-18 in bone metastasis.
Okamoto M; Azuma K; Hoshino T; Imaoka H; Ikeda J; Kinoshita T; Takamori S; Ohshima K; Edakuni N; Kato S; Iwanaga T; Aizawa H
Intern Med; 2009; 48(10):763-73. PubMed ID: 19443970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
